Clinical trials: Nonalcoholic Fatty Liver
Nonalcoholic Fatty Liver Disease
Effect of Iron Depletion by Phlebotomy Plus Lifestyle Changes vs. Lifestyle Changes Alone on Liver Damage in Patients With Nonalcoholic Fatty Liver Disease With Increased Iron Stores
Patients will be randomized to lifestyle changes alone or lifestyle changes associated with iron depletion. Iron depletion will be achieved by removing 350 cc of blood every 10-15 days according to baseline hemoglobin values and…
- Trial name
- NCT00658164
- Testing
- Iron depletion treatment
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Overweight and Obesity
A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight
AZD9550, previously being developed for the treatment NASH, is a dual GCG and GLP-1 receptor agonist. AZD9550 is now being developed in combination with AZD6234, a SARA, for the treatment of overweight and obesity and its…
- Trial name
- CONTEMPO (NCT06151964)
- Testing
- AZD9550, AZD9550 and AZD6234
- Where
- 15 sites in Austria, Canada and 3 more
- Volunteers
- 166 people
- Sponsor
- AstraZeneca
Fatty Liver, Nonalcoholic, Diet, Healthy
Glycemic Index/Saturated Fatty Acid Diet and Hepatic Fat
Excessive fat in the liver is associated with impairments in metabolic health. Reducing the amount of carbohydrates and fat both have been shown to reduce liver fat.
- Conditions
- Fatty Liver, Nonalcoholic, Diet, Healthy, Obesity
- Trial name
- NCT04054297
- Testing
- High GI/SFA diet, Low GI/SFA diet
- Where
- Netherlands
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Non-alcoholic Fatty Liver Disease (NAFLD)
Assessment of Hepatic Steatosis Using Dedicated Software Implemented on Ultrasound Devices
Non-alcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease, with an estimated prevalence of 5-30% in the general population and 55-80% in patients with type 2 diabetes.
- Trial name
- NCT07268937
- Testing
- CAP (Controlled Attenuation Parameter) module implemented on the Fibroscan machine.
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Diabetes Mellitus, Non Alcholic Fatty Liver Disease
Dapagliflozin in Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Mellitus Patients (T2DM).
Nonalcoholic fatty liver disease (NAFLD) encompasses conditions such as nonalcoholic steatohepatitis (NASH), which involves liver inflammation and fibrosis resulting from steatosis, potentially leading to cirrhosis and…
- Trial name
- NCT07020377
- Testing
- Dapagliflozin (DAPA), Negative control
- Where
- 2 sites in Egypt
- Volunteers
- 60 people
- Sponsor
- Amira Bisher,PhD
Fatty Liver, Nonalcoholic, Weight Loss
Feasibility of Immersive Virtual Reality Dietician Program in Metabolic-dysfunction Associated Steatotic Liver Disease
Metabolic-dysfunction associated steatotic liver disease, often referred to as "fatty liver disease", is a leading cause of liver failure.
- Conditions
- Fatty Liver, Nonalcoholic, Weight Loss, Virtual Reality, Implementation Science
- Trial name
- NCT06215131
- Testing
- In-person dietary weight loss counseling, Virtual reality dietary weight loss counseling
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Milton S. Hershey Medical Center
Metformin, Obesity, Abdominal
Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus
The purpose of this study is to analyze the effects of GLP-1RA on blood glucose, body weight, glucose and lipid metabolism and fat distribution in overweight/obese patients with type 2 diabetes mellitus.
- Conditions
- Metformin, Obesity, Abdominal, Diabetes Mellitus, Type 2, Abdominal Fat
- Trial name
- NCT05779644
- Testing
- Liraglutide, Semaglutide, Metformin
- Where
- China
- Volunteers
- 300 people
- Sponsor
- RenJi Hospital
Non-alcoholic Fatty Liver Disease (NAFLD)
Efficacy of Nutritional Therapy With High Methionine Content in the Treatment of NAFLD
To assess the effect of a methionine metabolism-based dietary strategy in patients with non-alcoholic fatty liver disease in order to reduce complications while improving the quality of life for patients.
- Trial name
- NCT04450875
- Testing
- Experimental group (with diet)
- Where
- Mexico
- Volunteers
- 121 people
- Sponsor
- Universidad Veracruzana
Non-Alcoholic Fatty Liver Disease
Liver Health and Metabolic Function in People With Obesity
This project aims to determine the effect of significant weight loss on rates on hepatic fibrogenesis in people with obesity.
- Trial name
- NCT03701828
- Testing
- Weight loss surgery
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
NASH, NAFLD
Assessment of Fatty Liver With Thermo-acoustic Device
The study will evaluate the accuracy of hepatic steatosis estimation by thermo-acoustic ultrasound with estimation by MRI-PDFF (Proton Density Fat Fraction) .
- Conditions
- NASH, NAFLD, Non-alcoholic Fatty Liver, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT04302051
- Testing
- Thermo-acuostic image acquisition of liver, MRI-PDFF estimation of hepatic fat
- Where
- United States
- Sponsor
- Medical College of Wisconsin
CKD, NAFLD
Prevalence of Non-alcoholic Fatty Liver Disease in Patients With Chronic Kidney Disease in Assiut
The goal of this observational study is to detect the prevalence of NAFLD in CKD patients The main question[s] it aims to answer are: [question 1] prevalence of NAFLD in CKD patients.
- Trial name
- NCT06009250
- Volunteers
- 200 people
- Sponsor
- Muhammad Ameen Abdelrady Abdelaziz
Nonalcoholic Steatohepatitis (NASH)
Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH
This is a phase 2, randomized, double-blind, placebo controlled study in adults with biopsy confirmed NASH. The study is aimed at evaluating efficacy and tolerability of ASC41 in adults with NASH.
- Trial name
- NCT05118360
- Testing
- ASC41 2 mg, ASC41 4 mg
- Sponsor
- Gannex Pharma Co., Ltd.
Non-alcoholic Steatohepatitis
Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)
A randomized, double-blind, placebo-controlled Phase II study，to evaluate the efficacy and safety of TQA2225/AP025 in Patients With Non-Alcoholic Steatohepatitis (NASH)
- Trial name
- NCT06569524
- Where
- 53 sites in China
- Volunteers
- 120 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Metabolic Dysfunction-Associated Steatotic Liver Disease, Pediatric Obesity
Non-Invasive Diagnostic Panel for MASLD in Children With Obesity
This prospective, single-center, two-group observational study evaluates a non-invasive multi-parameter diagnostic panel for metabolic dysfunction-associated steatotic liver disease (MASLD) in children with obesity.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Pediatric Obesity, Insulin Resistance Syndrome
- Trial name
- PedMASLD-Pilot (NCT07731360)
- Testing
- Non-Invasive Multi-Parameter Diagnostic Panel
- Where
- Turkey (Türkiye)
- Volunteers
- 180 people
- Sponsor
- Kayseri City Hospital
Non-alcoholic Fatty Liver Disease, NAFLD
Autonomic Dysfunction in Non-Alcoholic Fatty Liver Disease
There is a significant association between autonomic dysfunction and symptoms experienced by NAFLD patients mediated by increased systemic inflammation and insulin resistance, resulting in deteriorating quality of life of…
- Conditions
- Non-alcoholic Fatty Liver Disease, NAFLD, Fatty Liver, Nonalcoholic, Nonalcoholic Fatty Liver Disease
- Trial name
- AD-NAFLD (NCT02132780)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Virginia Commonwealth University
Diabetes Mellitus Type 2, Dyslipidemia
Low Calorie Diet and Diabetes
The primary hypothesis is to investigate whether a low calorie diet for 7 weeks followed by continuous lifestyle advice is an effective option to achieve an improvement in glucose control as measured by HbA1c after 52 and 104…
- Conditions
- Diabetes Mellitus Type 2, Dyslipidemia, Non-alcoholic Fatty Liver Disease, Obesity
- Trial name
- LCD (NCT02498990)
- Testing
- Low calorie diet followed by life style intervention
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Karolinska University Hospital
Fatty Liver Disease, Chronic Glomerular Disease
Metabolic Associated Fatty Liver Disease in Patients With Chronic Glomerular Disease
The association of metabolic associated fatty liver disease in patients with chronic glomerular disease
- Trial name
- NCT06691529
- Volunteers
- 500 people
- Sponsor
- Assiut University
NAFLD
Ketohexokinase Inhibition in NAFLD
Fructose is a big contributor to the development of non-alcoholic fatty liver disease (NAFLD). Inhibiting ketohexokinase (KHK), the enzyme catalyzing the first committed step in fructose metabolism, is thought to reduced…
- Trial name
- KHKi (NCT05463575)
- Testing
- Ketohexokinase inhibition
- Where
- Netherlands
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Nonalcoholic Fatty Liver Disease, NAFLD
Rifaximin in Fatty Liver Disease
TITLE Rifaximin in Fatty Liver Disease (RiFL) DESIGN Open-label pilot study HYPOTHESIS Reduction in gut flora by the antibiotic Rifaximin reduces hepatic inflammation in Non-Alcoholic Steatohepatitis (NASH).
- Conditions
- Nonalcoholic Fatty Liver Disease, NAFLD, Nonalcoholic Steatohepatitis
- Trial name
- RiFL (NCT01355575)
- Testing
- Rifaximin
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Imperial College London
Type 2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease
Diabetes, Exercise and Liver Fat (DELIVER)
This randomised controlled trial will determine if exercise (150 - 200 min per week, 6 weeks) can beneficially modify liver fat quality in non alcohol fatty liver disease patients with type 2 diabetes mellitus (n = 26, 13 per…
- Conditions
- Type 2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, Obesity, Insulin Resistance
- Trial name
- (DELIVER) (NCT04004273)
- Testing
- Exercise
- Where
- 4 sites in United Kingdom
- Volunteers
- 25 people
- Sponsor
- James King
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.